Galectin Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
12.00
10.00
7.00
7.00
1.00
-
Gross Income
12.00
10.00
7.00
7.00
1.00
-
SG&A Expense
12,092.00
15,270.00
20,072.00
21,474.00
16,246.00
13,602
EBIT
12,104.00
15,280.00
20,079.00
21,481.00
16,247.00
13,602
Unusual Expense
-
150.00
-
-
-
-
Non Operating Income/Expense
-
-
-
-
12.00
-
Pretax Income
12,088.00
15,788.00
20,027.00
21,436.00
16,235.00
13,900
Consolidated Net Income
21,080.00
16,017.00
20,027.00
21,436.00
16,235.00
13,900
Net Income
21,080.00
16,017.00
20,027.00
21,436.00
16,235.00
13,900
Net Income After Extraordinaries
21,080.00
16,017.00
20,027.00
21,436.00
16,235.00
13,900
Net Income Available to Common
21,947.00
16,960.00
21,124.00
22,350.00
17,467.00
15,047
EPS (Basic)
1.30
0.78
0.88
0.76
0.49
0.38
Basic Shares Outstanding
16,874.00
21,849.00
24,120.00
29,216.00
35,521.00
39,414
EPS (Diluted)
1.30
0.78
0.88
0.76
0.49
0.38
Diluted Shares Outstanding
16,874.00
21,849.00
24,120.00
29,216.00
35,521.00
39,414
EBITDA
12,092.00
15,270.00
20,072.00
21,474.00
16,246.00
13,602
Non-Operating Interest Income
16.00
42.00
52.00
45.00
24.00
38
Equity in Affiliates (Pretax)
-
400.00
-
-
-
-
Other After Tax Income (Expense)
8,992.00
229.00
-
-
-
-
Preferred Dividends
867.00
943.00
1,097.00
914.00
1,232.00
1,147
About Galectin Therapeutics
View Profile
